Trial Profile
A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel dose study of two doses of R935788 [R 788, fostamatinib] in rheumatoid arthritis patients failing to respond to methotrexate.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TASKI-2
- Sponsors Rigel Pharmaceuticals
- 28 May 2011 Health-related quality-of-life results presented at the 12th Annual Congress of the European League Against Rheumatism.
- 05 May 2011 AstraZeneca added as trial sponsor and lead trial cenre as reported by ClinicalTrials.gov.
- 30 Sep 2010 Results have been published in full in the New England Journal of Medicine.